SCHEMBL3533248

SCHEMBL3533248

Nc1cccc(-c2csc3ccnc(N)c23)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.68
AURKA O14965 5/20 0.68
AURKB Q96GD4 5/20 0.68
EPHB4 P54760 1/20 0.61
MAP4K4 O95819 5/20 0.54
ROCK2 O75116 4/20 0.52
RPS6KA5 O75582 4/20 0.52
LCK P06239 4/20 0.52
LYN P07948 4/20 0.52
RET P07949 4/20 0.52
FGFR1 P11362 4/20 0.52
FLT1 P17948 4/20 0.52
RPS6KB1 P23443 4/20 0.52
AXL P30530 4/20 0.52
FLT3 P36888 4/20 0.52
FRK P42685 4/20 0.52
CSNK1A1 P48729 4/20 0.52
CSNK1D P48730 4/20 0.52
CLK2 P49760 4/20 0.52
BLK P51451 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471696 0.86 KDR (0.61) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL31060331 0.81 KDR (1.00) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL3531281 0.81 KDR (1.00) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL28803622 0.80 KDR (0.79) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL27923016 0.79 KDR (0.64) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL3525533 0.77 EPHB4 (0.74) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL3531647 0.77 KDR (0.82) KDRAURKAAURKBMAP4K4ROCK2
SCHEMBL3534642 0.77 KDR (0.64) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL4471357 0.76 EPHB4 (1.00) KDRAURKAAURKBEPHB4MAP4K4
SCHEMBL3977000 0.76 KDR (0.55) KDRAURKAAURKBEPHB4MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103087078-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB 2013-05-08 CN disclosed
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
CN-1856498-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB (US) 2006-11-01 CN disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885AURKB 171/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885AURKB 171/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885AURKB 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.